CMS fi­nal­izes re­stric­tions on Bio­gen's Alzheimer's drug cov­er­age, will on­ly fund use in clin­i­cal tri­als

CMS late Thurs­day fi­nal­ized its de­ci­sion to re­strict cov­er­age for Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm and oth­er amy­loid-tar­get­ed drugs to just pa­tients par­tic­i­pat­ing in clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER